Can a smartwatch make virtual heart rehab work better?

NCT ID NCT07322510

First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 27 times

Summary

This study looks at whether a medical-grade smartwatch (CardioWatch 287-2) can improve a 13-week virtual cardiac rehab program for people with heart disease. About 216 participants will either use the watch or not, and researchers will compare their progress in areas like exercise, diet, and quality of life. The goal is to see if the watch helps doctors provide better remote care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mumford Professional Centre

    Halifax, Nova Scotia, B3L4P1, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Corsano CardioWatch 287-2 wearable device

What this could lead to

If successful, this could show that a wearable device helps make virtual cardiac rehab as effective as in-person programs, leading to better heart health for more patients.

What could go wrong

This is a small, early-stage study comparing two non-randomized groups, so results may not be definitive. The device may be uncomfortable or difficult to use, and not all phones are compatible.

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease cardiovascular disorder congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.